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Abstract: Platelets play important role in hemostasis (physiological), thrombosis and 
atherosclerosis (pathological). Changes in functional responses of platelets, due to 
presence of biochemical and biomechanical agonists, can contribute in onset and 
progression of cardiovascular diseases (CVD). Secondhand smoke (SHS) and altered 
shear stress in the vasculature are considered as biochemical and biomechanical risk 
factors for CVD. Though previous studies have investigated the effects of these two 
factors on change of platelet functions, none of the study have focused on how SHS and 
altered shear stress together can modulate platelet activation and aggregation. The main 
objective of this study was to investigate the combined effect of SHS and altered shear 
stress on platelet functions. Experiments were conducted in vitro on platelets by applying 
constant (1 and 3 Pa) or physiologically relevant dynamic (normal and elevated) shear 
stress in a cone-plate shearing device for 60 min, with or without the exposure of SHS 
(smoke of 1 cigarette/5 L). Platelet activation was quantified by platelet surface P-
selection expression using flow cytometry. Following the same procedure, platelet 
surface GPIbα and GPIIb expressions were also measured. Platelet aggregation 
parameters were measured from TRAP induced platelet aggregation using Chrono-log 
aggregometer. Simultaneously, Thromboxane B2 generation was quantified using a 
sandwich ELISA (enzyme immunoassay) approach. Results from this study indicated 
that, SHS enhanced shear induced platelet activation represented by enhanced platelet 
surface P-selectin expression. SHS with elevated constant (3Pa) shear stress significantly 
increased P-selectin expression. However, platelet surface GPIbα and GPIIb expressions 
remained unaffected in presence of the combined exposure. In addition, SHS and shear 
stress combinedly altered platelet aggregation response. Combined exposure of SHS and 
shear stress had no significant effect on accumulated Thromboxane B2. Thus, the 
observations of this study indicated that, exposure to environmental SHS can potentially 
cause detrimental effects on the cardiovascular system by enhancing platelet activation, 
especially in patients with CVD. 
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CHAPTER I 
 
 
INTRODUCTION 
 
Cardiovascular disease (CVD), characterized as any disorder that affects the 
cardiovascular system, is the number one killer disease worldwide as well as in the USA. 
According to the World Health Organization’s (WHO) estimation in 2008, around 17.3 
million people died of CVD, which is about 30% of global death1. According to the 
statistics conducted by American Heart Association (AHA) in 2009, 1 of every 3 deaths 
in the USA was caused by CVD2.  
Atherosclerosis is the most common type of CVD. Atherosclerosis is a complex 
long term process of lipid accumulation in the sub-endothelial layer of blood vessels. 
Atherosclerosis causes hardening of arteries and changes the geometry of the blood 
vessel by narrowing the vessel’s inner perimeter. Atherosclerosis can result in partial or 
complete occlusion of a blood vessel, which hinders the required blood flow into the 
downstream tissues and leads to scarcity of oxygen and nutrition in those tissues.  
Clinical observations have highlighted that atherosclerotic lesions preferentially 
localize to regions with complex vasculature. Vessels with complex geometry produce 
complex hemodynamic shear stress, which is considered as a risk factor for
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atherosclerosis development3. The presence of atherosclerotic plaque further disturbs 
local shear stress conditions. Altered shear stress plays a significant role in platelet 
activation, which is critical in coagulation and thrombosis4-6. 
Smoking increases the risk of CVD. Second hand smoke (SHS) is capable of 
imposing deleterious effects on the cardiovascular system7. Previous studies have 
reported that short term exposure to SHS can cause adverse effects on cardiovascular 
system8. Exposure to SHS alone can increase the risk of CVD about 30%9-11. SHS can 
also significantly affect platelet activation12. 
It is well established that both disturbed hemodynamic shear stress and 
secondhand smoke could affect platelet activation12;13. However, the combined effect of 
dynamic shear stress and SHS on platelet behavior has not been determined. 
The hypothesis of the present study is that the combined effect of altered shear 
stress and secondhand smoke could further enhance platelet activation and aggregation 
compared to their individual effect. The hypothesis will be tested through the following 
specific aims.  
Specific Aim 1: To study the effect of dynamic shear stress and SHS on platelet surface 
protein expression by measuring platelet surface P-selectin, GPIbα and GPIIb expression 
using flow cytometry.  
Specific Aim 2: To study the effect of dynamic shear stress and SHS on platelet 
aggregation induced by thrombin receptor activator peptide (TRAP). 
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Specific Aim 3: To investigate the effect of dynamic shear stress and SHS on 
Thromboxane A2/B2 generation from activated platelets.  
 Results obtained from this study could improve our understanding of platelet 
functional changes caused by altered dynamic shear stress and SHS, as well as the 
potential mechanisms associated, which may lead to new preventive or therapeutic 
solutions to atherosclerosis and other cardiovascular diseases. 
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CHAPTER II 
 
 
BACKGROUND 
 
2.1 Platelets 
Platelets are non-nucleated discoid shaped cells circulating through the blood. 
These cells are produced from megakaryocytes in the bone marrow. Platelet count is 
generally maintained in the range of 150,000-350,000 per µL of blood. They have 
approximate dimensions of 3 µm by 0.5 µm and remain functional in the circulation for 
about 10 days. After this duration, dead platelets are removed and blood is replenished 
with new platelets.  
Platelets have a tri-laminate cytoskeletal system that gives platelets their discoid 
shape and helps in enduring blood flow induced shear stress. The cytoskeletal lamina is 
comprised of a phospholipid bilayer, with inclusion of glycolipids, glycoproteins and 
cholesterol14. Platelets’ cytoplasm contain normal cellular organelles like mitochondria, 
lysosomes, endoplasmic reticulum, and platelet specific granules. Although platelets are 
non-nucleated cells, they contain some megakaryocyte derived mRNA which can 
synthesize some protein15. Regardless of this capacity, most of the proteins required for 
various physiological processes are present either in the storage granules or on the
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platelet membrane. Platelets contain two types of granules: α-granules and dense bodies. 
Between these two granules, α-granules are larger and most abundant in platelets. 
Approximately 50 to 80 α-granules are present in each platelet16. Contents of the α-
granules consist of several proteins including von Willebrand Factor (vWF), fibrinogen, 
fibronectin, vitronectin, thrombospondin, P-selectin, platelet factor 4, platelet derived 
growth factor (PDGF), and coagulation factor V. On the other hand, dense bodies contain 
ADP, ATP, calcium (Ca2+), serotonin and pyrophosphate17. The platelet membrane  
contains some glycoproteins such as GPIb-IX-V, GPIIb/IIIa, GPV and GPVI that 
regulate some of the platelet functions like adhesion and aggregation15. 
The major function of platelets is maintaining hemostasis. Apart from hemostasis, 
platelets are also involved in inflammatory responses which may lead to atherosclerosis, 
thrombosis and other cardiovascular diseases18. Hemostasis consists of several processes 
including coagulation, platelet adhesion, activation and aggregation. Hemostasis is a 
series of processes working in parallel to keep blood within the body by formation of 
blood clots, dissociation of clot, and healing of injured blood vessels. During vascular 
injury, the endothelial cell lining of the blood vessel wall becomes disrupted and the 
subendothelium is uncovered. Platelets start to become tethered and to roll along the 
endothelial cell surface using the platelet surface receptor P-selectin19. Adhesive 
molecules like collagen present in the subendothelium associate with plasma vWF (a 
multimeric protein) to mediate platelet adhesion. The platelet membrane receptor GPIb-
IX-V interacts with vWF to promote adherence to the vessel wall20. Multiple binding 
sites of vWF facilitates multiple platelet capturing and cause firm platelet adhesion. 
Another receptor, GPVI, also mediates platelet attachment to subendothelial collagen. 
6 
 
GPIb-IX-V to vWF interaction transduces a conformational signal and activates platelets 
initiating a series of complex processes. Conformational change from this interaction 
activates platelet membrane receptor GPIIb/IIIa, induces granular secretion, translocation 
of phospholipid, rearrangement of platelet cytoskeleton (leading to shape change), 
increases in surface area and formation of pseudopods. Phospholipid translocation moves 
negatively charged phospholipid from the inner surface to the outer surface of platelet 
membrane and provides an anionic surface for Ca2+ binding and coagulation. 
Thromboxane A2 (TXA2) and ADP/ATP, released by activated platelets, are capable of 
mediating further activation, and recruitment of neighboring platelets from the blood 
circulation. Following initial platelet adhesion, activated platelet surface receptor 
GPIIb/IIIa and GPIa/IIa bind to fibrinogen and collagen respectively, stabilizing initial 
adhesion21. Fibrinogen has two binding sites for the platelet GPIIb/IIIa receptor that 
enable platelet-platelet binding, forming platelet aggregates. Figure 2.1 shows the initial 
platelet adhesion, activation related secretion, and stable aggregate formation. 
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Figure 2.1: Platelet adhesion, activation and aggregation under blood flow22. 
Platelets can become activated in the presence of both biochemical and 
mechanical agonists. Important biochemical agonists are ADP, serotonin, thrombin 
(formed during coagulation), collagen and TXA2. Disturbed shear stress generated in 
diseased blood vessels or in complex vascular structures are termed as mechanical 
agonists4. 
2.2 Hemodynamic Shear Stress 
Hemodynamic shear stress generated by the flowing blood within the vasculature, 
is the most relevant mechanical force that can modulate platelet functions. Shear stress 
generated in blood vessels can induce intra-platelet and inter-platelet cell signaling, 
resulting in platelet activation, adhesion and aggregation. Platelet thrombus formation is 
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also modulated by physiological shear stress that can become unregulated in the presence 
of pathological shear stress conditions5. The presence of geometrical complexities like 
bifurcation, twisting and tapering in vascular regions alters the normal shear stress 
patterns, which may induce platelet activation. Activated platelets in the circulation pose 
a risk of atherosclerotic lesion formation, as they can secrete alpha granules and dense 
bodies packed with different adhesion molecules, coagulation factors (factor V), and 
generate microparticles17. Presence of atherosclerotic plaque in vessel lumens reduces 
vessel diameter, further disturbing the shear stress profile. Due to the effect of altered 
shear stress on platelet function and on cardiovascular disease progression, study of the 
effect of altered shear stress on platelet activity is of interest to many researchers.  
Hemodynamic shear stress is the mechanical shear force exerted by blood flow on 
the vascular wall and on the circulating blood cells. Considering blood as a Newtonian 
fluid, the generated shear stress can be calculated by the following relation: 
𝜏 = µ 
𝑑𝑢
𝑑𝑦
 
where, τ is the generated shear stress, µ is the effective dynamic viscosity of the fluid, 
and 
𝑑𝑢
𝑑𝑦
  is the velocity gradient towards the flow direction.  
Under physiological condition, the generated shear stress within healthy 
vasculature is between 10 to 30 dyne/cm2. Whereas, under pathological conditions, such 
as in the presence of atherosclerotic plaque in a stenosed vessel, shear stress can increase 
up to 380 dyne/cm2 23. Numerous studies have been conducted to investigate how altered 
shear stress can induce platelet functional changes like activation and aggregation3;24. 
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Brown et al. studied functional changes of platelets by applying constant shear stress (50, 
100 and 250 dyne/cm2) to measure platelet granule release and aggregation. Observations 
from their study included simultaneous platelet activation and aggregation at shear levels 
above 50 dyne/cm2, platelet lysis starting at shear levels of 100 dyne/cm2, and platelet 
fragmentation when the shear stress reaches 250 dyne/cm2 25. Sakariassen et al. utilized a 
higher shear stress (315 dyne/cm2) exposure for shorter duration (0.075 sec) and observed 
platelet activation within even this short period of shear exposure. In addition to that, 
these authors also concluded that prolonged shear exposure duration or a rapid increase in 
shear stress magnitude results in enhanced platelet activation26. In a study conducted by 
Hellums et al., an increased level of Ca2+ release from platelets and platelet aggregation 
was observed over 100 sec under shear stress exposure of 30, 60, 90 and 120 dyne/cm2. 
This study established that both shear stress magnitude and shear exposure time have 
important role in platelet activation4. This fact was further supported by Ramstack et al., 
who applied relatively higher shear stress varying between 300-1000 dyne/cm2 for a 
duration of 25-1650 msec, and found significant platelet activation at higher shear stress 
levels applied for lesser time. Summarizing the data from various studies an inverse 
relationship between shear stress magnitude and shear exposure time can be established, 
indicating both high and low shear stress can induce platelet activation when they are 
utilized to shear platelets for shorter and longer durations respectively27;28.  
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Figure 2.2: Relation between shear stress and exposure time for platelet activation 
(serotonin release) and hemolysis (red blood cell lysis) from summarized data of previous 
studies4.  
 
 
Though all these studies have investigated the effects of shear stress on platelet 
activation, most of them have utilized constant shear stress to activate platelets, which is 
not physiologically relevant. Rubenstein et al. used pulsatile shear stress varying between 
4 to 40 dyne/cm2 for 40 min to study the effect of more physiologically relevant dynamic 
shear stress on platelet activation and aggregation. Enhanced platelet activation was 
observed in response to a dynamic shear stress waveform with a transient high shear of 
40 dyne/cm2, compared to constant shear of 4.75 dyne/cm2. Enhanced platelet 
aggregation was also observed with dynamic waveforms having a peak of 40 dyne/cm2 13.  
Several techniques have been used experimentally to apply shear stress to 
platelets. A modified in vitro cell shearing device has been proposed by Blackman et al. 
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based on the cone-plate viscometer principle, which is able to apply not only constant 
shear stress but also complex shear waveforms29. In the current study the modified design 
was adopted to devise a cone-plate hemodynamic shearing device, which was used to 
investigate platelet responses under different shear stress conditions. The shear stress 
generated by this device is uniformly distributed throughout the fluid flow region and can 
be controlled precisely using a programmable controller. The hemodynamic cone-plate 
shearing device facilitates the application of dynamic shear stress waveforms obtained 
from numerical models of arterial flow. 
2.3 Secondhand Smoke (SHS) 
Second hand smoke (SHS), also termed environmental tobacco smoke (ETS), is 
mainly side stream smoke from the smoldering end of a cigarette. Tobacco smoke 
contains more than 4000 chemical compounds, among which approximately 250 
compounds are known to be either toxic or carcinogenic8;30. SHS exposure is a critical 
risk factor that has no threshold for safe level of exposure (implying that the risk 
associated will be zero only at no SHS exposure). SHS exerts deleterious effect on 
physiological systems including the cardiovascular system8. SHS exposure affects 
inflammatory responses and atherosclerotic plaque progression, increasing the risk of 
pathological consequences by 30 percent9-11. Whincup et al., in a 20 year prospective 
study of passive smoking and coronary heart disease, found that risk of heart disease 
produced by passive smoking is nearly similar to that of light active smoking31.  
SHS exposure hampers the equilibrium condition of normal hemostasis32 by 
modulating platelet function33. The impact of SHS on platelets is reported to be as potent 
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as that of mainstream smoke12. Studies have indicated that platelet activation and 
aggregation increases with SHS exposure leading to unregulated thrombus formation34. 
Unregulated thrombus formation and the presence of activated platelets in the circulation 
contribute to formation, and growth of atherosclerotic plaque6;35. The first study 
quantifying platelet activation by SHS was conducted by Benowitz et al. Human subjects 
(smokers and non-smokers) were exposed to SHS for 20 min. In this study, enhanced 
platelet activation was found in non-smokers exposed to SHS compared to control (non-
smokers not exposed to SHS)36. Several animal studies have also indicated that passive 
smoking contributes to atherosclerotic plaque growth and decreased bleeding time by 
enhancing platelet activities (activation, adhesion) 37-39. Rubenstein et al. conducted an in 
vitro study, and exposed platelets to 12 dyne/cm2 of shear stress and SHS (at the 
concentration of smoke from 1 cigarette per 5 L of washed platelets) for up to 30 min in a 
circulation flow loop, and observed increased platelet activation12.  
In summary, although numerous studies have been conducted to investigate the 
effects of shear stress and SHS on platelet functions separately, not many studies have 
examined the combined effects of dynamic shear stress and SHS on activation and 
aggregation of platelets. 
2.4 Platelet Surface Protein Expression 
Platelet surface proteins play a significant role in modulation of platelet functions. 
Protein expression is subject to change in the presence of different agonists, as various 
agonists induce different level of platelet activation. As previously mentioned, 
hemodynamic shear stress and SHS are two such factors that can cause changes in 
13 
 
platelet function, leading to various levels of surface protein expression. Therefore in our 
study protein expression of platelets subjected to shear stress and SHS was used for 
quantifying platelet activation. Common techniques for assessment of platelet surface 
protein expression include flow cytometry40;41 and enzyme linked immunosorbent assay 
(ELISA)42. Flow cytometry is the most widely used method for platelet surface protein 
quantification, and this technique was used in this study. 
2.4.1 P-selectin Expression 
P-selectin is the largest glycoprotein of the selectin family at 140 kDa molecular 
weight. Under normal conditions P-selectin remains stored in the membrane of α-
granules43. Upon activation, P-selectin of α-granules redistributes on the platelet surface 
as a result of degranulation44. Activated platelets express approximately 10,000 P-selectin 
receptors on their surface45. Among all of the platelet surface glycoproteins, P-selectin is 
considered to be the most reliable activation marker, due to its overexpression during 
platelet activation46;47. 
P-selectin is involved in the rolling and tethering of platelets on endothelium48. P-
selectin plays a major role in adhesion by assisting rolling of platelets49 and by recruiting 
more platelets. Along with cell-cell adhesion, P-selectin also initiates positive feedback 
which further activates endothelium. P-selectin is also considered to have an important 
function in platelet-platelet aggregation, and to aid in stable GPIIb/IIIa-fibrinogen 
binding50.  It is also important in developing large stable platelet-leukocyte aggregates51. 
Under pulsatile shear stress at stenosed/atherogenic regions, P-selectin is involved in 
shear induced aggregation52. Results from previous studies have established that P-
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selectin mediates thrombogenesis, atherogenesis and contributes to cardiovascular 
disease progression45;51. 
Its involvement in pathological conditions like atherogenesis has made P-selectin 
a platelet marker of interest. Shear stress itself may cause platelet activation, which is 
evident from up-regulation of P-selectin expression53. Several groups have conducted in 
vitro studies to observe the expression of P-selectin on the platelet surface under different 
shear stress conditions. Goto et al. observed a significant increase in P-selectin 
expression after applying shear stress at the rate of 10,800 s(-1) on platelets54. Lu et al. 
applied 10, 15 and 20 Pa (1 Pa = 10 dyne/cm2) shear stress on platelets in whole blood for 
120 sec and found a significant increase in P-selectin expression with the increase in 
shear stress magnitude47. Zhang et al. used 100 dyne/cm2 shear stress on platelets in 
platelet rich plasma and washed platelets in their study for short durations (10-20 sec), 
where minimal changes in P-selectin expression were observed. This study indicated that 
the duration of shear application, together with shear stress magnitude, are important for 
inducing changes in platelet P-selectin expression55. Rubenstein et al. applied several 
different shear conditions including constant shear of 4.75, 10, 40 dyne/cm2 and pulsatile 
flow (varying from 4 to 40 dyne/cm2) on washed platelets for 40 min, and observed an 
increase in the expression of P-selection with increased shear stress-exposure duration13. 
In another study conducted by Farzana et al., constant shear (1, 3, 10 and 30 dyne/cm2) 
and dynamic shear stress (normal shear varying from 1 to 10 dyne/cm2, recirculation 
shear varying from 0.6 to 4 dyne/cm2, and elevated shear varying from 1 to 65 dyne/cm2) 
was applied on washed platelets for 60 min. Results from this study indicated that there 
was no significant change in P-selectin expression under dynamic shear conditions. 
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However, under constant shear conditions, a significant increase in P-selectin expression 
was observed with increased shear stress magnitude56. Increased platelet activation due to 
the higher shear loading conditions with constant shear stress results in the fuse of more 
α-granules with platelet membrane resulting in an increased P-selectin expression on 
surface. 
Along with shear stress, SHS is also considered to be a major risk factor for 
cardiovascular disease progression. Rubenstein et al. used SHS (at the concentration of 
smoke from 1 cigarette per/5 L) and found SHS to be a potent factor for platelet 
activation under normal flow conditions12. Though there have been many studies 
investigating the effect of shear stress and SHS on P-selectin expression separately, the 
combined effect of SHS and shear stress on P-selectin expression remains to be 
determined. Therefore the goal of this study was to investigate the separate effect of the 
two factors, as well as the combined effect of shear stress and SHS on P-selectin 
expression by platelets. 
2.4.2 GPIbα Expression 
Platelet surface receptor GPIb/V/IX is a complex composed of four 
transmembrane glycoprotein subunits, among which GPIbα plays a key role. GPIbα is 
non-covalently bound with other glycoprotein subunits (GPIbβ, GPV and GPIX) to form 
the complex57. GPIbα is the main binding site of the complex with an approximate 
molecular weight of 170kDa58. Approximately 25,000 GPIb/V/IX complexes are present 
on the resting platelet membrane59.  
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GPIbα can initiate platelet adhesion through GPIbα interaction with plasma or 
subendothelial vWF during vascular injury. In the presence of high shear stress, GPIbα 
adheres to the subendothelial associated vWF, which triggers a conformational signal 
leading to platelet activation60. The GPIbα-vWF interaction simultaneously activates the 
platelet surface GPIIb/IIIa receptor, resulting in subsequent platelet aggregation61.  
In addition, the initial GPIbα-vWF adhesion facilitates platelets rolling on the 
subendothelium, slows down the platelet, and provides more time for platelet-
subendothelium interaction resulting in stable adhesion62. GPIbα also contains binding 
sites for thrombin, which enables activation of platelets in the presence of thrombin63.  
Since shear stress can modulate platelet surface GPIbα expression, several studies 
have been conducted to observe the effect of shear stress on expression of this protein. Li 
et al. applied low level (100, 150, 1,000 s-1) and high level (3000 s-1) of shear stress for 7 
min on whole blood to measure GPIb/V/IX complex expression on platelet surface64. 
Their results indicated that GPIb/V/IX expression was unchanged at low shear stress 
levels, while increased initially (for 1 min) and then decreased with time under high shear 
stress. In another study by Leytin et al., GPIbα expression was measured after shearing 
platelet rich plasma under physiological (10-44 dyne/cm2) and pathological (117-388 
dyne/cm2) shear stress conditions for 90 sec65. GPIbα expression was found to be 
unchanged by physiological shear, whereas a pathological level of shear stresses 
decreased platelet surface GPIbα expression. White et al. applied shear stress (1000 s-1) 
for longer duration (up to 20 min) on washed platelets and observed no change in 
GPIb/V/IX expression on the platelet surface66. Results from several studies have 
indicated that SHS can affect platelet activation and aggregation; however, platelet 
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surface GPIbα or GPIb/V/IX complex expression in the presence of shear stress and SHS 
has not been quantified in any studies12;67. Therefore, the goal of this study was to 
quantify the combined effect of SHS and shear stress on platelet surface GPIbα 
expression.  
2.4.3 GPIIb Expression 
The GPIIb/IIIa complex, also known as αIIbβ3, is a platelet surface glycoprotein 
that plays a major role in platelet aggregation. Approximately 80,000 GPIIb/IIIa 
receptors are  presented on each platelet surface68. GPIIb/IIIa is a member of the integrin 
family, which  contains two transmembrane glycoprotein subunits (GPIIb and GPIIIa) 
associated by non-covalent bonding69. Both subunits are equally important for binding 
and function of the GPIIb/IIIa complex70. Glycoprotein GPIIb has a molecular weight of 
about 136 kDa and is directly involved in ligand binding71. GPIIb/IIIa can bind several 
soluble ligands including fibrinogen, fibronectin, thrombospondin, and vWF72. On resting 
platelets, this integrin remains in an inactive (low affinity) state and cannot bind with the 
ligands. However, during platelet activation, degranulation of alpha and dense granules 
causes an increase in platelet surface GPIIb/IIIa receptor73 and transduces a 
conformational change to activate (high affinity ligand binding state) the receptor that 
enables ligand binding74.    
Following platelet activation, GPIIb/IIIa mainly binds to fibrinogen facilitating 
firm adhesion61. Dimeric fibrinogen also enables binding of two adjacent platelets 
through GPIIb/IIIa-fibrinogen-GPIIb/IIIa cross-linking leading to platelet aggregation. 
Under high shear stress conditions, GPIb/V/IX-vWF interaction mediates shear induced 
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platelet activation resulting in GPIIb/IIIa receptor activation and stable aggregate 
formation mediated by GPIIb/IIIa-vWF interaction75.  
Due to its importance in platelet adhesion and aggregation, many studies have 
investigated the effects of mechanical and biochemical agonists on platelet surface 
GPIIb/IIIa. Li et al. applied low level (100, 150, 1,000 s-1) and high level (3000 s-1) 
shear stress for 7 min on whole blood to measure GPIIb/IIIa receptor expression on the 
platelet surface64. Their results indicated that GPIIb/IIIa expression increased at low shear 
stresses, but decreased at higher shear stress. Zhang et al. applied 100 dyne/cm2 shear 
stress on washed platelets and platelet rich plasma for 10-20 sec and observed minimal 
change in GPIIb/IIIa expression55. Though several studies have examined the effect of 
shear stress on GPIIb expression, the effect of SHS on platelet GPIIb receptor expression 
under different shear stress conditions has yet to be elucidated. Therefore, this study 
aimed to quantify platelet surface GPIIb expression in the presence of shear stress and 
SHS, and to compare the results with the corresponding expression of normal resting 
platelets. 
2.5 Platelet Aggregation 
Platelet aggregation is another process by which platelets contribute to 
hemostasis. The aggregation mechanism of platelets has been discussed in section 2.1. 
Enhanced platelet aggregation or unregulated thrombus formation can be an indication of 
cardiovascular disease progression, as these processes can result in vascular occlusion 
76;77.  
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Platelet aggregation can be measured in vitro using several methods including 
turbidimetric aggregometry, impedance aggregometry, flow cytometry, and 
lumiaggregometry78-82. Turbidity aggregometry measures optical transmittance in platelet 
rich plasma, whereas impedance aggregometry measures electrical impedance in whole 
blood. Flow cytometry is less common method. Lumiaggregometry can measure platelet 
aggregation and platelet dense granule secretion simultaneously in whole blood. In this 
study, we chose to use turbidity aggregometry to measure platelet aggregation. 
Since notable changes of platelet aggregation are considered as a hallmark of 
cardiovascular disease, platelet aggregation has been studied extensively under different 
conditions. Moake et al. applied constant shear stress of 30-60 dyne/cm2 for 30 sec on 
washed platelets and observed enhanced platelet aggregation83.  In a similar study, Chow 
et al applied 15, 30, 60, 90, and 120 dyne/cm2 shear stress on washed platelets for 100 
sec and observed increased platelet aggregation with the increase in shear stress 
magnitude84. Rubenstein et al. found a significant increase in platelet aggregation at 10 
and 40 dyne/cm2 compared to 4.75 dyne/cm2 shear stress. Davis et al., in a human study, 
observed increased platelet aggregation when human subjects were exposed to SHS for 
20 min85. In another study by Rubenstein et al., an increased platelet aggregation was 
detected when washed platelets were exposed to SHS at the concentration of smoke of 1 
cigarette per 5 L for 4 hr67. Since aggregation of platelets is an important indication of 
change in platelet function, our goal was to determine the combined effect of SHS and 
shear stress on platelet aggregation potential.  
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2.6 Platelet Thromboxane A2/B2 
Thromboxane is a subfamily of lipids that are known as eicosanoids. 
Thromboxane A2 (TXA2) and thromboxane B2 (TXB2) are the two major thromboxanes 
produced by activated platelets. Upon activation by various agonists (including ADP, 
collagen, and thrombin), phospholipids of the platelet membrane are hydrolyzed into 
arachidonic acid. Oxygenation of arachidonic acid produces prostaglandin H2, which in 
turn is converted into TXA2 by thromboxane A2 synthase
86. TXA2 induces a positive 
feedback mechanism, which enhances further platelet activation and promotes platelet 
aggregation by recruiting more platelets87;88. However, TXA2 is chemically unstable, and 
has a short half-life (about 32 sec) at normal body temperature in biological fluids 
(plasma, urine)89. At the end of this short life, TXA2 is metabolized into TXB2 and 
excreted from human body via urine.  
As only activated platelets synthesize thromboxane A2/B2, an increased level of 
plasma thromboxane indicates platelet activation. Both TXA2 and TXB2 can promote the 
onset and progression of atherosclerotic events in the vasculature90. An increased level of 
TXA2 formation has been observed in patients with heart disease
91;92 and 
atherosclerosis93. Due to its pro-aggregatory activity, TXA2 is considered to be an 
important factor for maintaining hemostasis and contributing to thrombosis. Studies have 
indicated that TXA2 acts as a positive feedback element and can modulate platelet shape 
change and granular secretion94. In an animal study using stenotic canine coronary 
arteries, Aiken and Bush et al. reported prevention of arterial thrombosis by a 
thromboxane synthase inhibitor95;96. Findings from this study indicated that TXA2 is 
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involved in thrombotic events. Fuse et al. observed a higher level of plasma TXB2 in 
congenital heart disease patients97.  
In a human study conducted by Kritz et al., an increased level of plasma TXB2 
was detected in both smokers and non-smokers after they were exposed to passive 
smoke98. Passive smoking (SHS) enhances platelet activation and aggregation34, 
suggesting that SHS could also enhance thromboxane release. Similarly, shear induced 
platelet activation could also enhance TXA2 synthesis in platelets. Though several 
pharmacological studies have measured plasma thromboxane levels under various 
pathological conditions, not many studies have correlated platelet thromboxane release 
with risk factors such as altered shear stress and SHS. Since inhibition of the TXA2 
formation pathway and TXA2 dependent platelet activation can be a potent tool to reduce 
CVD99-102, investigating the level of TXA2/TXB2 generation by platelets exposed to 
altered shear stress and SHS is clinically important in developing new therapies for CVD.
22 
 
CHAPTER III 
 
 
MATERIALS AND METHODS 
 
3.1 Platelets 
Platelet pheresis bags were obtained from the Oklahoma Blood Institute. Platelets 
were separated from the plasma by centrifugation at 3000 rpm (1100×g) for 9 min. The 
supernatant (platelet poor plasma, PPP) was  then discarded and platelet pellets were re-
suspended in HEPES buffered modified Tyrode’s solution (HBMT: 137 mM sodium 
chloride, 2.7 mM potassium chloride, 0.36 mM monobasic sodium phosphate, 12 mM 
sodium bicarbonate and 2 mM magnesium chloride, 0.2% BSA, 0.1% dextrose, and 
0.01mL/mL of HEPES buffer (0.01 M – pH 7),  pH 7.4). Platelet count was adjusted to 
250,000/µL. Washed platelets were kept under mild agitation on a shaker at room 
temperature (RT), and used within 5 hour of preparation. Washed platelets were used to 
measure platelet surface protein expression using flow cytometry. Platelet rich plasma 
(PRP) was used for platelet aggregation and thromboxane B2 generation experiments. 
PRP was diluted using the autologous platelet poor plasma (PPP), and the final platelet 
count was adjusted to 250,000/µL. 
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Washed platelets or platelet rich plasma were treated with shear stress and/or second 
hand smoke to investigate the combined or separate effect of shear stress and SHS on 
platelet responses.  
3.2 Shear Stress Treatment 
3.2.1 Cone-Plate Shearing Devices 
 Different constant and dynamic shear stress was applied to platelets in a cone-
and-plate shearing device. The cone-plate shearing device is a standard device to apply 
shear stress to cells103. Figure 3.1 represents the schematic view of the cone-plate 
shearing device. Shear stress generated in the cone and plate shearing device can be 
calculated using Equation (1).  
(1)

 

 
where, τ is the generated shear stress, µ is the dynamic viscosity of the fluid, ω is angular 
velocity and α is the cone angle. 
 
Figure 3.1: Schematic diagram of the basic cone-plate shearing device applying uniform 
shear stress on the fluid flow domain104. 
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 Since the dynamic viscosity of the fluid µ and the cone angle α are constant, shear 
stress in the flow field can be precisely controlled by adjusting the angular velocity of the 
cone. Under laminar flow conditions, shear stress is uniformly distributed throughout the 
flow domain. Two types of cone and plate shearing devices (single cone-plate and 6 well 
cone-plate) were used in this study. 
A. Single Cone-Plate Shearing Device 
The single cone-plate shearing device is shown in Figure 3.2. The diameter of the 
cone was 49.18 mm, and the angle of the cone was 2°. The maximum shear stress that 
can be generated by this device is 7.2 Pa (for laminar flow). Experiments were conducted 
in a 60-mm petri-dish containing approximately 3 ml of sample.  
 
Figure 3.2: Hemodynamic Single Cone-plate shearing device used in this study for 
platelet shearing. 
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B. 6-well Cone-Plate Shearing Device 
The design of the 6-well cone-plate device is similar to that of the single cone-
plate dev1ice. This device (shown in Figure 3.3) had four cones, which can fit in the 
wells of a 6-well cell culture plate. The diameter of each cone was 34.66 mm, and the 
cone angle was 0.5°. The maximum shear stress generated by this device is 12 Pa (for 
laminar flow). Approximately 0.85 ml of sample was added to each well of the 6-well 
plate for shearing. 
 
Figure 3.3: Hemodynamic 6-well cone-plate shearing device used in this study for 
platelet shearing. 
Both shearing devices were used to shear platelets in different experiments 
depending on the volume of sample required for the downstream analysis. Angular 
velocity for both devices was adjusted accurately to keep the generated shear stresses 
identical. No variation was observed, using these two shearing devices to produce the 
same shear stress. Washed platelets and PRP were exposed to various shear stress 
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waveforms in the two shearing devices for 60 min (at RT). 
3.2.2 Shear Stress Profiles 
 Two different types of shear stress were used in this study: 1) Constant shear 
stress at 1 and 3 Pa, and 2) Physiologically relevant dynamic (normal and elevated) shear 
stresses. 1 Pa was chosen to mimic the physiologically relevant normal mean shear 
stress105;106, and 3 Pa to simulate the patho-physiological elevated shear stress condition 
in a diseased blood vessel. The pulsatile normal shear stress varied between 0.1 Pa and 1 
Pa, mimicking shear stress conditions in a normal coronary artery. The pulsatile elevated 
shear stress was used to mimic shear stress experienced by platelets as they passed a 
stenosis. While the cells were passing through the simulated stenosis throat, they were 
exposed to high shear stress at 6.5 Pa for a short duration of time (~ 0.1 sec), and as they 
exited the diseased region shear stress applied to them returned to the normal level. The 
dynamic shear stress waveforms that were utilized in this study to stimulate platelets are 
shown in Figure 3.4.  
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Figure 3.4: Shear stress profile of platelets passing through the left coronary artery under 
physiological and pathological conditions107. 
 
3.3 Secondhand Smoke Treatment 
Side stream smoke, or secondhand smoke (SHS), was extracted from Marlboro 
cigarettes in HBS buffer (pH 7.4). Smoke extract was collected from the smoldering end 
and did not pass through any filters. The extraction procedure reported by Yin et al. was 
followed for SHS extraction108. Smoke extract was collected in the buffer at the 
concentration of smoke of 1 cigarette/50 mL. For all experiments SHS was used at a final 
concentration of smoke of 1 cigarette/5L, mimicking exposure to secondhand smoke 
from one cigarette. Platelets (both washed platelets and platelet rich plasma) were treated 
with SHS by mixing SHS extract at the specified concentration, followed by 60 min 
incubation (RT). Combined treatment with SHS and shear stress was attained by addition 
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of SHS extract (at the specified concentration) and then application of the desired shear 
stress on platelets for 60 min (RT).  
3.4 Platelet Response Quantification 
Platelet responses to SHS and/or shear stress were quantified through the 
measurement of platelet surface protein expression, platelet aggregation, and platelet 
thromboxane B2 release as described below. 
3.4.1 Platelet Surface P-selectin, GPIbα and GPIIb Expression 
Washed platelets were treated with SHS and/or shear stress for 60 min. Untreated 
washed platelets were used as a negative control, and thrombin receptor activator peptide 
(TRAP at 20µM, 5 min, RT) activated platelets were used as a positive control. TRAP 
activated platelet represents complete platelet activation.  
 Post treatment platelet surface P-selectin expression was measured by incubating 
platelets with FITC conjugated monoclonal mouse anti-human P-selectin antibody 
(CD62P, Ancell Corporation, Bayport, MN) at 1:50 dilution (30 min, RT, in the dark). 
Samples were then diluted in HBMT (1:10) and read immediately using a flow cytometer 
(Accuri C6, Ann Arbor, MI).  
 Platelet surface GPIbα and GPIIb expression were also measured following the 
same procedure as for P-selectin.expression. FITC conjugated monoclonal mouse anti-
human GPIbα anti-body (CD42b, Abcam, Cambridge, MA) at 1:10 dilution for (30 min, 
RT, in the dark) and FITC conjugated monoclonal mouse anti-human GPIIb antibody 
(CD41a, Ancell Corporation, Bayport, MN) at 1:50 dilution (30 min, RT, in the dark) 
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were used respectively for platelet surface GPIbα and GPIIb protein expression 
measurement. FITC conjugated MOPC antibody (MOPC, Ancell Corporation) was used 
at 1:100 dilution (30 min, RT, in the dark) to detect non-specific binding. 
Platelet surface protein expression measurements were recorded by the cflow 
(Accuri C6) computer interface. The mean fluorescence value of specific platelet surface 
proteins was obtained from flow cytometry and was used for further data analysis. Data 
were normalized to the respective negative control of the same day to account for the 
variation in platelet donor. Therefore, there was no variations due to different platelet 
donors in the final data analysis. 
3.4.2 Platelet Aggregation 
 Normalized PRP samples were treated with SHS and/or shear stress for 60 min 
and untreated PRP samples served as control. Aggregation in response to thrombin 
receptor activator peptide (TRAP, 20µM) was measured at 37°C, using an optical 
aggregometer (Chrono-Log Corporation, Model 490-2D, Havertown, PA). All the points 
for the aggregation curve were recorded using a computer interface program (Aggrolink). 
Using these saved points, the slope of the aggregation curve, percent aggregation, and 
maximum percent of aggregation were calculated. Slope and percent aggregation were 
calculated using a MATLAB program (which is included in the appendix) and maximum 
percent aggregation was obtained directly from the recorded points of aggregation. The 
slope for the first 60 points represents the rate at which platelets participate in TRAP 
induced aggregation. Percent aggregation quantifies the percentage of platelets 
participating in aggregation, whereas the maximum percent aggregation means the 
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maximum percentage of platelets participating in aggregation induced by TRAP. All the 
data were normalized to the respective control, to address variation from different platelet 
bags at different days. 
3.4.3 Thromboxane B2 (TXB2) Assay 
Activated platelets can release thromboxane A2 which rapidly transforms into 
thromboxane B2. Using a Thromboxane B2 Express EIA kit (monoclonal, Cayman 
Chemical Company) the thromboxane B2 (TXB2) level was measured in plasma.  After 
SHS and/ or shear stress treatment, PRP samples were centrifuged at 3000 rpm for 6 min. 
Platelet poor plasma (PPP) was collected and applied to a microtiter plate pre-coated with 
goat polyclonal anti-human antibody. Untreated PPP was used as control. Next TXB2 
tracer and TXB2 monoclonal antibody were added (2 hr, RT, on orbital shaker) for 
binding with the polyclonal antibody in the wells. The Amount of TXB2 antibody tracer 
complex bounded to the goat polyclonal antibody was detected by using Ellman’s reagent 
(1hr, RT, on orbital shaker, in the dark) through color change. Color development was 
measured using a microplate reader (BioTek Instruments, ELx800) at 405nm. Color 
intensity was inversely proportional to the amount of TXB2 present in the wells. TXB2 
express EIA standard (supplied with the assay kit) was used at different dilutions to 
obtain a linear relationship between color intensity and TXB2 concentration. The 
concentration of TXB2 in the plasma was calculated by comparing results with the linear 
relation obtained from the TXB2 standard. Data normalization with respect to the control 
sample was conducted to avoid variations from different platelet bags at different days. 
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3.5 Statistical Analysis 
For each platelet surface protein, expression (all mean fluorescence, AMF) values 
were obtained using flow cytometry and the values were normalized to negative control.  
In platelet aggregation experiments from the collected aggregation points 
(obtained using aggregometer), slope of the aggregation curve, percent aggregation, and 
maximum percent of aggregation were calculated. Following normalization with respect 
to control all the three parameters were used for data analysis.  
The concentration of thromboxane B2, which was released by the platelets in 
plasma, was obtained from the optical density (OD) values obtained from the 
thromboxane B2 assay. Thromboxane B2 concentrations were normalized to the control 
sample prior to further analysis. 
All data obtained from these experiments were normalized to the respective 
resting platelet control data for statistical data analysis. Single factor ANOVA was 
conducted to determine if there was any significant effect from SHS and shear stress 
treatment on platelet responses. If a significant difference was detected, Student-
Newman-Keuls post hoc test was performed for multiple comparisons. Microsoft Excel 
and Statistical Analysis System (SAS 9.3) software was used for all statistical analysis 
with a significance level of α =0.05. 
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CHAPTER IV 
 
 
RESULTS 
 
4.1 Platelet Surface Protein Expressions 
Platelet surface protein expression was measured after exposing washed platelets 
to second hand smoke (SHS) and/or shear stress for 60 min. Constant shear stress of 1 or 
3 Pa or dynamic shear stress of pulsatile normal (varying from 0.1 to 1 Pa) or pulsatile 
elevated (varying from 0.1 to 6.5 Pa) was applied to washed platelets using a 
hemodynamic cone-plate shearing device. SHS treatment, was applied by adding SHS 
extract to washed platelets. Flow cytometry was used to quantify platelet surface proteins, 
utilizing fluorescent antibody binding with individual surface proteins. All mean 
fluorescence (AMF) values were obtained for each platelet protein. AMF values were 
used to compare the platelet surface protein expressions among different experimental 
conditions to investigate the effect of SHS and shear stress. At the first step, platelets 
treated with shear stress and SHS separately were compared with control platelets 
(resting platelets without any treatment) to look at the individual effect of these two 
treatments. Then platelets treated with both shear stress and SHS were compared with 
shear stress treated platelets to determine whether the effect of two factors are 
significantly different compared to the shear effect. AMF values for all experimental  
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conditions were normalized to the respective control value (resting platelets without SHS 
and shear stress) before all the comparisons to avoid variation from different platelet 
donors and experiments at different days. 
4.1.1 P-selectin Expression 
Treated washed platelets (exposed to SHS and/or shear stresses for 60 min) were 
incubated with FITC conjugated P-selectin antibody for 30 min and analyzed using a 
flow cytometer. Figure 4.1 shows histograms for P-selectin fluorescence intensity of 
platelet population. The positive control TRAP induced highest shift in fluorescence 
intensity for platelet population which is consistent with maximum activation. Higher 
shear stress loading showed shift in fluorescence intensity for increased platelet 
population. 
 
Figure 4.1: Representative P-selectin expression plots under combined effect of shear 
stress and SHS from flow cytomerty. Histograms showing activated platelet population 
shift of different combined treatment. 
Fluorescence Intensity 
Control 
TRAP 
SHS 
Elevated 
shear + SHS 
Normal 
shear + SHS 
1 Pa shear + 
SHS 
3 Pa shear + 
SHS 
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Normalized AMF values of platelet P-selectin expression for different conditions 
are shown in Figure 4.2. Statistical analysis using one way ANOVA showed a significant 
differences (P-value < 0.0001) in platelet P-selectin expression under the different 
conditions.  Table 4.1 summarizes the P-values for the comparison of P-selectin 
expression among different conditions using Student-Newman-Keuls multiple 
comparison.  
Platelets exposed to SHS, 1 Pa and 3 Pa have significantly (P-value < 0.05) 
increased P-selectin expression compared to that of resting platelets. SHS, 1 Pa and 3 Pa 
shear stress increased the average P-selectin expression by about 24%, 22% and 34% 
respectively compared to control. Therefore, both SHS and constant shear stress can 
induce platelet activation and increase P-selectin expression. Dynamic shear stresses 
(normal and elevated shear stress) did not show any effect on platelet P-selectin 
expression. Comparison between the two constant shear stress conditions shows that the 
effect of 1 Pa (1.22 ± 0.295, n=9) and 3 Pa (1.34 ± 0.27, n=9) shear stress was not 
significantly different. Similarly, no significant difference was observed in the effect of 
both dynamic shear stress of pulsatile normal (1.01 ± 0.1, n=7) and pulsatile elevated 
(0.98 ± 0.08, n=6). The combination of SHS and 3 Pa shear stress induced a significant 
increase in P-selectin expression (1.74 ± 0.25, n=9) compared to shear stress exposure at 
3 Pa (1.34 ± 0.27, n=9) and SHS exposure (1.24 ± 0.35, n=32). No interaction between 
dynamic shear stress and SHS was observed, and P-selectin expression was unaffected by 
their combined exposure.  
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Figure 4.2: P-selectin expression on platelet surface after applying different shear stress 
and SHS. All mean fluorescence (AMF) values were normalized to CTR (resting platelets 
without SHS). All data (sample size, n = 6 - 9) are presented as mean + SD (standard 
deviation).  
The results demonstrated that both constant shear stress and SHS exposure 
independently had a significant effect on platelet P-selectin expression, while dynamic 
shear stress showed no significant effect. In addition, higher magnitude of shear stress 
and SHS had significant effect on P-selectin expression. 
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Table 4.1: Summary of P-values obtained from multiple comparisons of P-selectin 
expression under different conditions. One way ANOVA p-value < 0.0001. N.S. 
indicates not significant. 
Sample 
size, n= 
32 32 9 9 9 9 6 6 7 6 
  CTR SHS Shear 10 
SHS + 
Shear 10 
Shear 30 
SHS + 
Shear 30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 0.0002                   
Shear 10 0.0205 
(N.S) 
0.8054 
                
SHS + 
Shear 10 
0.0003 
(N.S) 
0.2661 
(N.S) 
0.2771 
              
Shear 30 0.0005 
(N.S) 
0.32 
(N.S) 
0.3208 
____             
SHS + 
Shear 30 
<.0001 <.0001 ____ 0.0012 0.0008           
Elevated 
(N.S) 
0.8803 
0.0203 ____ ____ ____ ____         
SHS + 
Elevated 
(N.S) 
0.916 
0.0383 ____ ____ ____ ____ 
(N.S) 
0.8436 
      
Normal 
(N.S) 
0.8797 
0.0301 ____ ____ ____ ____ 
(N.S) 
0.815 
____     
SHS + 
Normal 
0.0355 
(N.S) 
0.9415 
____ ____ ____ ____ ____ 
(N.S) 
0.1219 
(N.S) 
0.115 
  
 
4.1.2 GPIbα Expression 
Platelet surface GPIbα Expression was measured by flow cytometric analysis in a 
similar manner as for measuring P-selectin expression. After flow cytometric analysis, 
normalized fluorescence intensity values were compared among different experimental 
conditions. Normalized AMF values of platelet GPIbα expression for different conditions 
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are shown in Figure 4.3. Statistical analysis using one way ANOVA shows significant 
differences (P-value < 0.0001) among different conditions. Table 4.2 condenses the P-
values for comparisons among different conditions.  
 
Figure 4.3: GPIbα expression on platelet surface after applying different shear stress and 
SHS. All mean fluorescence (AMF) values were normalized to CTR (resting platelets 
without SHS). All data (sample size, n = 6 - 8) are presented as mean + SD (standard 
deviation).  
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Table 4.2: Summary of P-values obtained from multiple comparisons of GPIbα 
expression under different conditions. One way ANOVA p-value < 0.0001. N.S. 
indicates not significant. 
Sample 
size, n= 
29 29 8 8 7 7 6 6 6 7 
  CTR SHS 
Shear 
10 
SHS + 
Shear 
10 
Shear 
30 
SHS + 
Shear 
30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 
(N.S) 
0.4504 
                  
Shear 
10 
(N.S) 
0.2148 
(N.S) 
0.0837 
                
SHS + 
Shear 
10 
(N.S) 
0.8529 
(N.S) 
0.7554 
(N.S) 
0.2547 
              
Shear 
30 
0.0005 0.0024 0.0002 ____             
SHS + 
Shear 
30 
<0.0001 <0.0001 ____ 0.0004 
(N.S) 
0.4034 
          
Elevated 
(N.S) 
0.7651 
(N.S) 
0.8857 
____ ____ ____ ____         
SHS + 
Elevated 
0.0191 
(N.S) 
0.0555 
____ ____ ____ ____ 
(N.S) 
0.109 
      
Normal 
(N.S) 
0.2101 
(N.S) 
0.4154 
____ ____ ____ ____ 
(N.S) 
0.4567 
____     
SHS + 
Normal 
(N.S) 
0.9656 
(N.S) 
0.6072 
____ ____ ____ ____ ____ 
(N.S) 
0.0537 
(N.S) 
0.2964 
  
 
Enhanced GPIbα expression was observed with the condition of shear stress level 
of 3 Pa (1.36 ± 0.29, n=7) compared to control, which shows an average increase of 
GPIbα expression by 36%. SHS and other shear loading conditions (1 Pa, pulsatile 
normal, pulsatile elevated) did not show any significant changes of platelet GPIbα 
expression compared to control platelets. The effect of constant shear stress of 3 Pa was 
also elevated compared to 1 Pa (0.88 ± 0.17, n=8) shear stress, whereas both normal (1.13 
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± 0.2, n=6) and elevated (1.03 ± 0.07, n=6) pulsatile shear stress did not show significant 
difference in their effects. Combined effect of SHS and shear stresses (for both constant 
and dynamic shear) was also insignificant compared to the effect of shear stress and SHS 
separately. The results indicated that only constant high shear stress had a significant 
effect on GPIbα expression of platelets and no significant effect of combined treatments 
of shear stress and SHS was observed. 
4.1.3 GPIIb Expression 
Flow cytometric analysis was conducted for GPIIb expression as for P-selectin 
expression as described earlier. AMF values obtained from flow cytometry were 
normalized to control (resting platelets without SHS). Figure 4.4 shows all normalized 
AMF values of platelet GPIIb expression for different conditions represented as mean 
and standard deviation. Statistical analysis using one way ANOVA shows significant 
differences (P-value = 0.0023) in platelet GPIIb expression under different conditions.  
Table 4.3 summarizes all P-values for the comparisons of GPIIb expression among 
different conditions.  
From figure 4.4 we observed that in SHS treated platelets (0.93 ± 0.12, n=24) 
GPIIb expression was down regulated from control (resting platelets without SHS). 
Platelets exposed to different shear stress loading conditions did not display significant 
differences in GPIIb expression in contrast to control. Not only were shear stress effects 
insignificant compared to control, but there were no significant differences in response 
between constant shear of 1 Pa (0.98 ± 0.04, n=7) and 3 Pa (0.95 ± 0.13, n=5). Similarly, 
the effect of dynamic shear of normal intensity (0.96 ± 0.07, n=7) was insignificant 
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compared to elevated (0.97 ± 0.07, n=6) shear stress. The combined effect of SHS and 
shear stress on platelets demonstrated down regulation of GPIIb expression compared to 
shear treated platelets, but this change was observed for two specific shear stresses (1 Pa 
and pulsatile elevated). The results here indicate that SHS had a significant effect on 
platelet GPIIb expression, while shear stress had no effect. SHS combined with 1 Pa and 
pulsatile evevated shear caused decreased GPIIb expression. 
  
Figure 4.4: GPIIb expression on platelet surface after applying different shear stress and 
SHS. All mean fluorescence (AMF) values were normalized to CTR (resting platelets 
without SHS). All data (sample size, n = 5 - 7) are presented as mean + SD (standard 
deviation).  
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Table 4.3: Summary of P-values obtained from multiple comparisons of GPIIb 
expression under different conditions. One way ANOVA p-value = 0.0023. N.S. 
indicates not significant. 
Sample 
size, n= 
24 24 7 7 5 5 6 6 7 6 
  CTR SHS 
Shear 
10 
SHS + 
Shear 10 
Shear 
30 
SHS + 
Shear 30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 0.0246                   
Shear 
10 
(N.S) 
0.7059 
(N.S) 
0.2499 
                
SHS + 
Shear 
10 
<.0001 0.012 0.0036               
Shear 
30 
(N.S) 
0.2828 
(N.S) 
0.7938 
(N.S) 
0.5306 
____             
SHS + 
Shear 
30 
(N.S) 
0.3771 
(N.S) 
0.6501 
____ 0.0261 
(N.S) 
0.8811 
          
Elevated 
(N.S) 
0.5121 
(N.S) 
0.4327 
____ ____ ____ ____         
SHS + 
Elevated 
0.0002 0.0155 ____ ____ ____ ____ 0.0117       
Normal 
(N.S) 
0.3465 
(N.S) 
0.5565 
____ ____ ____ ____ 
(N.S) 
0.8491 
____     
SHS + 
Normal 
(N.S) 
0.2033 
(N.S) 
0.8697 
____ ____ ____ ____ ____ 0.0403 
(N.S) 
0.7491 
  
 
4.2 Platelet Aggregation 
Platelet rich plasma (PRP at 250,000 platelets per µL) prepared from the platelet 
bag was exposed to SHS (smoke of 1 cigarette/5L of PRP) and/ or shear stress (1 Pa, 3 
Pa, pulsatile normal and pulsatile elevated) for 60 min. The aggregation test was 
performed in the presence of an external agonist (TRAP- thrombin receptor activator 
peptide, at 20 µM concentration) using a chronolog turbidity aggregometer. Optical 
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transmittance was measured in the aggregometer through PRP in comparison with 
autologous platelet poor plasma (PPP). Light transmittance of PPP was set to 100 percent 
by setting it as reference and transmittance of the PRP sample to be measured was set as 
baseline with zero percent light transmittance initially. Figure 4.5 shows plots from 
aggregation test performed using the aggregometer. The aggregation plots show that the 
initial light transmittance was zero percent, and started increasing after the addition of the 
external agonist at 30 sec time. During aggregation light transmittance continued 
inreasing, until aggregation stabilizes (at around 5 min). The difference of light 
transmittance between the stabilized state and the initial state is termed as percent change 
of aggregation. Here plot A shows about 58 percent aggregation and B shows about 59 
percent aggregation of PRP samples.  
                      
Figure 4.5: Aggregation plot obtained for PRP using the agonist TRAP (20 µM) in 
aggregometer. Initial light transmittance was adjusted to 0%, indicating no aggregation, 
and PPP was considered to have 100% transmittance. With initiation of aggregation the 
light transmittance increased gradually. A- Aggregation plot of control (resting PRP 
without SHS), B- aggregation plot of PRP treated with SHS. 
A B 
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For PRP under experimental conditions, all aggregation data points were recorded 
for about 5 min. From these data points three aggregation parameters were calculated, 
which were utilized to investigate the effects of SHS and shear stress on platelet 
aggregation. Those three parameters are aggregation slope for the first 30 sec, change of 
aggregation percentage, and maximum percentage of aggregation. For each experiment, 
obtained results were normalized to respective control (resting platelets without SHS) to 
account for the variation from different platelet donors. All results were presented as 
mean ± standard deviation. Finally using statistical analysis, results were compared to 
identify the effects of different experimental conditions. Aggregation of control platelets 
was first compared to SHS treated and then to shear stress treated platelets to observe if 
these two factors independently can cause any change in platelet aggregation. After that, 
aggregation of platelets treated with both SHS and shear stress was compared to that of 
shear exposed platelets. The last comparison was done to observe the significance of the 
combined effect of these two factors (SHS and shear stress) on platelet aggregation.  
 4.2.1 Aggregation Slope for first 30 sec 
Platelet aggregation slope for the first 30 sec was calculated using the recorded 
aggregation data. Figure 4.6 shows the summarized results of aggregation slope. P-values 
for multiple comparisons among different conditions are presented in the table 4.4. From 
these comparisons we observed that SHS did not affect platelet aggregation slope 
significantly. Shear stress independently has a significant effect on platelet aggregation 
slope. Slope of aggregation decreased under the exposure to constant shear stress of 1 Pa 
(0.49 ± 0.11, n=7), 3 Pa (0.31 ± 0.18, n=6), and pulsatile shear stress of normal (0.64 ± 
0.13, n=5), elevated (0.64 ± 0.14, n=6). Slope of aggregation for first 30 sec represents 
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the rate at which platelets are participating in aggregation. In essence, both constant and 
pulsatile shear stress was capable of inducing change in platelet aggregation rate. Besides 
that, the effect of constant shear at 3 Pa was significant over the effect of 1 Pa shear 
stress, while the effect of dynamic shear stress of pulsatile elevated and pulsatile normal 
was alike. 
 
Figure 4.6: Slope of aggregation for first 30 sec after applying different shear stress and 
SHS on PRP. Aggregation slope values were normalized to CTR (resting platelets 
without SHS). All data (sample size, n = 5 - 7) are presented as mean + SD (standard 
deviation).  
The combined effect of SHS and constant shear stress was also significant, but not 
different from shear stress effect. The combined effect of SHS and dynamic shear stress 
shows increase in aggregation slope, while normal pulsatile combined with SHS caused 
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significant increase. The results indicated that, only shear stress had significant effect, 
whereas SHS did not show any effect on aggregation slope under the experimental 
condition.  
Table 4.4: Summary of P-values obtained from multiple comparisons of aggregation 
slope for first 30 sec under different conditions. One way ANOVA p-value < 0.0001. 
N.S. indicates not significant. 
Sample 
Size, n= 
24 24 7 7 6 6 6 6 5 5 
  CTR SHS 
Shear 
10 
SHS + 
Shear 10 
Shear 
30 
SHS + 
Shear 30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 
(N.S) 
0.2003 
                  
Shear 
10 
<.0001 <.0001                 
SHS + 
Shear 
10 
<.0001 <.0001 
(N.S) 
0.7425 
              
Shear 
30 
<.0001 <.0001 0.0008 ____             
SHS + 
Shear 
30 
<.0001 <.0001 ____ 0.0003 
(N.S) 
0.5744 
          
Elevated <.0001 <.0001 ____ ____ ____ ____         
SHS + 
Elevated 
<.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.0889 
      
Normal <.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.9281 
____     
SHS + 
Normal 
0.0004 <.0001 ____ ____ ____ ____ ____ 
(N.S) 
0.1275 
0.004   
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4.2.2 Aggregation Percentage Change 
Percentage change of aggregation was calculated from the difference of 
aggregation percentage of final state during aggregation testing and initial state for all 
experimental conditions. Summarized results of percentage change of aggregation are 
presented in figure 4.7. Table 4.5 contains the P-values for multiple comparisons among 
different experimental groups.  
Percentage change of aggregation indicates the percentage of the platelet 
population participating in aggregate formation. Increased percentage of aggregation 
represents higher platelet numbers in aggregate. The effect of SHS on percentage change 
of platelet aggregation was insignificant compared to control platelets. All four shear 
stress profiles independently had a significant effect on percentage change of platelet 
aggregation. Percentage change of aggregation decreased under the exposure to constant 
shear stress of 1 Pa (0.09 ± 0.14, n=6), 3 Pa (0.07 ± 0.1, n=6) and pulsatile shear stress of 
normal (0.53 ± 0.24, n=5) or elevated levels (0.38 ± 0.29, n=6). So, all shear stress 
conditions had a significant effect on platelet numbers participating in aggregation. The 
difference between 1 Pa and 3 Pa was not significant. Likewise, for dynamic shear stress 
there was no significant between normal and elevated pulsatile shear. The combined 
effect of SHS and shear stress (0.78 ± 0.15, n=5) was significant for pulsatile normal 
shear stress waveform compared to the shear effect (0.53 ± 0.24, n=5), while both 
dynamic shear stress waveforms combined with SHS increased aggregation percent 
change. All the other conditions did not show a significant effect of combined treatments. 
To sum up, SHS had no effect on platelet aggregation percentage change, while shear 
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stress had significant effect, and interaction between these two factors (SHS and shear 
stress) was limited to dynamic shear stress waveforms. 
 
Figure 4.7: Percentage change of aggregation after applying different shear stress and 
SHS on PRP. Aggregation percentage values were normalized to CTR (resting platelets 
without SHS). All data (sample size, n = 5 - 6) are presented as mean + SD (standard 
deviation).  
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Table 4.5: Summary of P-values obtained from multiple comparisons of aggregation 
percentage change under different conditions. One way ANOVA p-value < 0.0001. N.S. 
indicates not significant. 
Sample 
Size, n= 
24 24 6 6 6 6 6 6 5 5 
  CTR SHS 
Shear 
10 
SHS + 
Shear 
10 
Shear 
30 
SHS + 
Shear 
30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 
(N.S) 
0.1467 
                  
Shear 
10 
<.0001 <.0001                 
SHS + 
Shear 
10 
<.0001 <.0001 
(N.S) 
0.9667 
              
Shear 
30 
<.0001 <.0001 
(N.S) 
0.7544 
____             
SHS + 
Shear 
30 
<.0001 <.0001 ____ 
(N.S) 
0.8023 
(N.S) 
0.9834 
          
Elevated <.0001 <.0001 ____ ____ ____ ____         
SHS + 
Elevated 
<.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.3081 
      
Normal <.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.0821 
____     
SHS + 
Normal 
0.0019 0.0001 ____ ____ ____ ____ ____ 0.0003 0.0053   
 
4.2.3 Maximum Percentage of Aggregation 
From the obtained data of platelet aggregation by aggregometer, maximum 
percentage of aggregation values were calculated for all conditions. Figure 4.8 displays 
maximum aggregation percentages for platelets under all experimental conditions. 
Following the figure all P-values for designed multiple comparison among different 
conditions are shown in table 4.6.  
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Figure 4.8: Maximum percentage of aggregation after applying different shear stress and 
SHS on PRP. Maximum aggregation percentage values were normalized to CTR (resting 
platelets without SHS). All data (sample size, n = 5 - 6) are presented as mean + SD 
(standard deviation).  
From the results, a significant effect of shear stress (all shear loading conditions) 
was observed on the maximum percentage of platelet aggregation in comparison with 
resting platelets. Both constant shear stress of 1 Pa (0.32 ± 0.11, n=6), 3 Pa (0.19 ± 0.14, 
n=6) and pulsatile shear stress of normal (0.62 ± 0.17, n=5), and elevated levels (0.53 ± 
0.2, n=6) resulted in decreased maximum percentage of aggregation. In contrast, SHS 
was not able to exert a significant effect on the maximum percentage of platelet 
aggregation under resting condition. Comparisons between the effect of shear stress 
conditions revealed that constant shear stress of 3 Pa was significantly different than 1 Pa 
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shear, whereas there was no difference between the effect of normal and elevated 
pulsatile shear stress.  
Table 4.6: Summary of P-values obtained from multiple comparisons of maximum 
percentage of aggregation under different conditions. One way ANOVA p-value < 
0.0001. N.S. indicates not significant. 
Sample 
Size, n= 
24 24 6 6 6 6 6 6 5 5 
  CTR SHS 
Shear 
10 
SHS + 
Shear 10 
Shear 
30 
SHS + 
Shear 30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 
(N.S) 
0.1359 
                  
Shear 
10 
<.0001 <.0001                 
SHS + 
Shear 
10 
<.0001 <.0001 
(N.S) 
0.6475 
              
Shear 
30 
<.0001 <.0001 0.0344 ____             
SHS + 
Shear 
30 
<.0001 <.0001 ____ 
(N.S) 
0.0581 
(N.S) 
0.8191 
          
Elevated <.0001 <.0001 ____ ____ ____ ____         
SHS + 
Elevated 
<.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.1907 
      
Normal <.0001 <.0001 ____ ____ ____ ____ 
(N.S) 
0.1216 
____     
SHS + 
Normal 
0.0003 <.0001 ____ ____ ____ ____ ____ 0.0009 0.0034   
 
Dynamic shear stress combined with SHS induced an increase in maximum 
aggregation percent, and combined effect of SHS and pulsatile normal pulsatile shear 
stress (0.81 ± 0.09, n=5) was significant over shear effect (0.62 ± 0.17, n=5) for 
maximum aggregation percentage. For constant shear stress, the combined effect of SHS 
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and shear stress was not significant for maximum percentage of platelet aggregation. 
Thus, shear stress had a significant effect on maximum aggregation percentage, whereas 
SHS had no effect. Interaction with SHS was observed for dynamic shear stress 
waveforms. 
4.3 Platelet Thromboxane Release 
Platelet rich plasma (PRP at 250,000 platelets per µL) prepared from the platelet 
bag was exposed to SHS (smoke of 1 cigarette/5L of PRP) and/ or shear stress (1 Pa, 3 
Pa, pulsatile normal and pulsatile elevated) for 60 min. Thromboxane synthesized by 
platelets is released in the plasma, so PPP (platelet poor plasma) was separated from the 
PRP by centrifugation to perform the thromboxane B2 (TXB2) assay. The concentration 
of TXB2 was obtained from the TXB2 assay as described in the Materials and Methods 
section. For each experiment, obtained results were normalized to respective control 
(resting platelets without SHS) to account for the variation from different platelet donors. 
All results were presented with mean and standard deviation. Finally, using statistical 
analysis, results were compared to study the effects of different conditions. The control 
sample was first compared to SHS treated and then to shear stress treated sample to 
observe if these two factors independently cause any change in platelet thromboxane 
synthesis. After that, TXB2 concentration for platelets treated with both SHS and shear 
stress was compared to shear exposed platelets. The last comparison was conducted to 
observe the effect of the combination of these two factors (SHS and shear stress) on 
platelet thromboxane release.  
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Figure 4.9 represents all the results in graphical form with mean and standard 
deviation. Significant differences for comparisons are also shown in the figure. Table 4.7 
shows all P-values for conducted comparisons among experimental groups using Student-
Newman-Keuls multiple comparison. 
 
Figure 4.9: TXB2 concentration in plasma after applying different shear stress and SHS 
on PRP. Concentration values were normalized to CTR (resting platelets without SHS). 
All data (sample size, n = 4) are presented as mean + SD (standard deviation).  
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Table 4.7: Summary of P-values obtained from multiple comparisons of TXB2 
concentration under different conditions (sample size, n = 4). One way ANOVA p-value 
= 0.0004. N.S. indicates not significant. 
  
CTR SHS 
Shear 
10 
SHS + 
Shear 10 
Shear 
30 
SHS + 
Shear 30 
Elevated 
SHS + 
Elevated 
Normal 
SHS + 
Normal 
SHS 
(N.S) 
0.8404 
                
  
Shear 
10 
0.0006 0.001               
  
SHS + 
Shear 
10 
0.0005 0.0008 
(N.S) 
0.9541 
            
  
Shear 
30 
0.0003 0.0005 
(N.S) 
0.7957 
____           
  
SHS + 
Shear 
30 
0.0005 0.0009 ____ 
(N.S) 
0.9656 
(N.S)   
0.8068 
        
  
Elevated 0.0007 0.0011 ____ ____ ____ ____       
  
SHS + 
Elevated 
0.0014 0.0024 ____ ____ ____ ____ 
(N.S) 
0.7847 
    
  
Normal 0.0011 0.0018 ____ ____ ____ ____ 
(N.S) 
0.8629 
____   
  
SHS + 
Normal 
0.0008 0.0014 ____ ____ ____ ____ ____ 
(N.S) 
0.8516 
(N.S) 
0.9312 
  
 
SHS treatment here did not show any effect on TXB2 concentration, whereas 
shear stress (all four shear stress conditions) significantly increased TXB2 concentration. 
The average increase in TXB2 concentration due to the exposure to shear stresses can be 
expressed as 66% under 1 Pa, 71% under 3 Pa, 62% under pulsatile normal, and 65% 
under pulsatile elevated shear stress condition. Comparison between shear stress 
conditions did not show any significant difference. As shown in the table 4.7, between 1 
Pa (1.66 ± 0.35, n=4) and 3 Pa (1.71 ± 0.22, n=4) of constant shear stress, and also 
between dynamic normal (1.62 ± 0.21, n=4) and elevated (1.65 ± 0.32, n=4) pulsatile 
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shear stress there were no significant differences. The combination of SHS and shear 
stress exposure for 60 min also did not show any significant enhancement over shear 
stress alone. From the results, it is evident that SHS did not affect platelet thromboxane 
release and no added effect was observed when used in combination with shear stress. 
Shear stress itself significantly enhanced platelet thromboxane formation. 
55 
 
CHAPTER V 
 
 
DISCUSSION 
 
Cardiovascular disease (CVD) poses a major health risk in the United States. 
Circulating blood platelets are susceptible to various shear stress patterns generated in 
vasculature, especially under vascular disease conditions. Shear induced changes in 
platelet function contributes to initiation and progression of CVD. Recently, secondhand 
smoke (SHS) has been established as a potent risk factor for pathogenesis of CVD. 
However, the combined effect of various shear stress patterns and SHS on platelet 
functions has not been established yet, leaving a gap in understanding the combined 
effect. This study was aimed to investigate the combined effect of different shear stress 
profiles and SHS on platelet functions.  
  Numerous studies have investigated the effect of shear stress on platelets, 
although most of these studies are limited to the use of constant shear stress. This study 
investigated the effects on platelet functions using both constant and physiologically 
relevant dynamic shear stress using a feasible cone-plate hemodynamic shearing 
device29;109;110. The shear stress profiles utilized in this study were chosen to observe the 
change in platelet functions under both physiological and pathological level of shear 
stress. 1 Pa of constant shear stress represented physiological shear,
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while 3 Pa was used for pathological level of shear. Similarly for dynamic shear, 
physiological and pathological level of shear stress was represented by normal and 
elevated pulsatile shear stress respectively. Both waveforms were obtained from a 
previous study conducted in our laboratory111. Normal shear stress waveform varies 
between 0.1 and 1 Pa over one cardiac cycle (~ 0.9 sec), while elevated shear stress 
waveform varies similar to the normal waveform with a very short exposure to high shear 
stress magnitude (6.5 Pa for 0.1 sec once every 90 sec). 
 Platelet functional changes measurement were done using standard methods. 
Platelet function as well as surface glycoproteins can be measured effectively using flow 
cytometry112;113. Platelet aggregation has been established as the ‘gold standard’ for 
platelet function measurement114. Agonist induced platelet aggregation evaluation using 
aggregometer and thromboxane B2 measurement using immunoassay, both of these 
methods has been using for platelet function analysis115-117.  
5.1 Platelet Activation (Surface P-selectin Expression) 
Constant and dynamic shear stress had a different kind of impact on surface P-
selectin expression. Constant shear stress of 1 and 3 Pa significantly increased platelet 
surface P-selectin expression, while dynamic shear stress (normal and elevated) had no 
effect on P-selectin expression. Similar results were observed in a study conducted by 
Rubenstein et al., where a significant increase in platelet surface P-selectin expression 
was observed under constant shear stress (1 Pa and 4 Pa) after  40 min of shear 
exposure13. Another study from our group by Yin et al. reported that dynamic (normal, 
low, and elevated) shear stress did not enhance P-selectin expression of platelets118. The 
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lack of effect of dynamic shear stress on platelet P-selectin expression could be attributed 
to the relatively low shear stress loading on platelets compared to constant shear stress.  
The difference in shear loading on platelets is described by the shear stress-
exposure time integral value as defined by Rubenstein et al.13. In their study, Rubenstein 
et al. found that the pulsatile shear waveform resulted in significantly reduced levels of 
platelet activation compared to constant shear waveforms of similar peak magnitude. In 
this present study, shear stress-exposure time integral values were approximately 1980 
Pa·s for pulsatile normal and 2088 Pa·s for pulsatile elevated; while for constant shear 
stress of 1 and 3 Pa these values were 3,600 and 10,800 Pa·s respectively. Hence the 
results indicate that, P-selectin expression was highly sensitive to shear stress-exposure 
time integral value.  
SHS also significantly increased platelet P-selectin expression. Similar to our 
current observation, enhanced platelet activation in the presence of SHS has been 
observed in previous studies12;36. Further, the combination of SHS and shear stress (both 
constant and dynamic shear stress) had increased platelet P-selectin expression compared 
to individual effect of shear stress for all shear conditions. Interestingly, the combined 
effect of high magnitude constant shear stress and SHS revealed a significant increase in 
P-selectin expression compared to all other treatment conditions. This could potentially 
be due to the higher shear stress-time integral value of the high magnitude constant shear 
waveform. Together the data indicate that these two biochemical and mechanical agonists 
could enhance platelet activation. 
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5.2 Platelet Surface Protein Expressions 
Experimental results from this study indicated that constant shear stress of 3 Pa 
induced a significant increase in platelet surface GPIbα expression, while 1 Pa constant 
shear had no significant effect. Also, dynamic shear stress (pulsatile normal and pulsatile 
elevated) did not induce any change in GPIbα expression. This finding was in agreement 
with the observation of a study by White et al., where platelet surface activation and 
constant shear stress did not cause any reduction in platelet surface GPIb/V/IX receptor66. 
Constant shear stress of 3 Pa had increases GPIbα expression compared to other shear 
conditions which could be due to the variation in shear stress-time integral value. Higher 
constant shear (3 Pa shear) induced increase in GPIbα expression could possibly be 
mediated by a mechanism, which is different than that of other shear conditions. Another 
conclusion that can be drawn from this reasoning is GPIbα expression is more sensitive 
to shear stress-exposure time integral value.  
On the other hand, SHS had no significant effect on platelet surface GPIbα 
expression. In addition, the combined effect of SHS and shear stress had no significant 
effect on platelet surface GPIbα expression compared to the effect of individual factors. 
Though, SHS (individually and combined with shear stress) induced elevated platelet 
activation as measured by increased P-selectin expression, no change in GPIbα 
expression was observed. This indicates that P-selectin and GPIbα are regulated by 
distinct pathways. 
Further, it was observed from the results that platelet surface GPIIb expression 
was unaffected by shear stress (both constant and dynamic shear stress). This observation 
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implies that, changes in the platelet aggregation under varying shear stress conditions are 
not necessarily mediated by the effects of shear stresses on the platelet GPIIb expression. 
However, SHS individually caused a significant decrease in surface GPIIb expression. 
The down regulation of this surface protein could be attributed to receptor clustering, 
translocation and consumption by activated platelets119;120.  
SHS combined with shear stress of constant 1 Pa and pulsatile elevated induced a 
significant decrease of GPIIb expression compared to the individual effect of SHS or 
shear stress. Combined effect of SHS and shear stress (constant 1 Pa and pulsatile 
normal) did not display any change in GPIIb expression. Thus, when combined with the 
exposure of 1 Pa and elevated shear stress, the effect of SHS was intensified leading to 
significant decrease of GPIIb expression. This also indicates that different pathways or 
mechanisms were affected differently under various conditions which is demonstrated by 
the effect on GPIIb expression. 
5.3 Platelet Aggregation 
With platelet aggregation, slope for the first 30 sec of aggregation curve 
representing how fast platelets form aggregates when activated by external agonist was 
first investigated. Shear stress (both constant and dynamic shear stress) exposure caused a 
significant decrease of aggregation rate in agonist induced aggregation. Constant shear 
stress demonstrated more impact on aggregation rate than dynamic shear (both normal 
and elevated pulsatile shear), which could be attributed to the variation in shear time 
integral values as explained before.  
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The impact of SHS on aggregation rate was insignificant. Similarly, no 
enhancement of platelet aggregation was observed by Lardi et al., when platelets were 
exposed to SHS (60 min exposure)121. Combined exposure of constant shear and SHS 
have resulted no change in aggregation rate, but dynamic shear stress combined with SHS 
increased aggregation rate. The results also revealed that combined effect of normal 
pulsatile shear and SHS enhanced aggregation rate significantly compared to normal 
shear effect. However, dynamic shear stress is interacting with SHS, showing opposite 
treatment effect as dynamic shear causing decrease in aggregation rate while SHS 
causing increase. Altogether, it indicates that combined exposure of shear stress (both 
constant and dynamic shear stress) and SHS have no intensified effect on platelet 
aggregation compared to shear stress effect.  
To further investigate the effect of SHS and shear stress waveforms on 
aggregation, aggregation percent change and maximum percentage of aggregation was 
observed for agonist induced aggregation. Shear stress individually induced significant 
effect on both aggregation percent change and maximum percentage of aggregation. 
Dynamic shear stress had reduced impact than constant shear stress, which could be due 
to the variation in shear stress time integral.  
SHS exposure did not induced significant change in aggregation percentage 
changes, which is in accordance with previous study121. Constant shear stress with SHS 
exposure induced no effect on platelet aggregation percent changes when applied 
together. Dynamic shear stress combined with SHS induced increase in platelet 
aggregation percent changes. The difference in induced effects by constant and dynamic 
shear stress when combined with SHS could be attributed to the variation in shear stress-
61 
 
time integral. Dynamic shear stress and SHS shows opposite effect on platelet 
aggregation percent change similar to aggregation rate. It indicates that SHS is not 
inducing further effect on shear (both constant and dynamic shear stress) induced platelet 
aggregation, as expected compared to shear induced aggregation percentage. 
In a study conducted by Ikeda et al., platelets were found to be aggregating even 
while they were stimulated in the shearing device122. The shear induced aggregation 
could potentially affect the post shearing agonist induced aggregation observed. Further, 
continuous platelet activation with shear stress exposure was observed in a parallel study 
conducted in our laboratory56. This transient platelet activation while being sheared could 
also potentially have affected platelet aggregation, which was not possible to quantify 
due to the experimental limitation of this study. 
5.4 Platelet Thromboxane B2 Release 
Effect of shear stress and SHS on TXB2 concentration was investigated in the 
present study to determine whether thromboxane synthesis is affected under the 
experimental conditions. All shear stress treatment conditions induced a significant 
increase in TXB2 concentration at the end of 60 min exposure duration. Previous studies 
had also reported shear induced TXB2 synthesis
123;124. The TXB2 concentrations observed 
under different shear stresses were not significantly different. However, transient changes 
in TXB2 concentrations were not measured in this study.  
SHS alone did not show any impact on TXB2 at the end of 60 min exposure. A 
previous human study reported an increase in thromboxane generation caused by passive 
smoking98, where neighboring cells of platelets could possibly influence the thromboxane 
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synthesis pathway. Another possible reason for the discrepancy between the current 
results and the human data is that the SHS extract used in this study may not be identical 
in composition to passive smoke exposure. Combined exposure of SHS and shear stress 
had no significant effect on accumulated TXB2 at the end of exposure duration. Thus, 
SHS separately or along with the exposure of shear stress did not induce any change in 
thromboxane synthesis.  
Previous studies have established that TXB2 is able to induce pro-aggregatory 
activity. SHS alone did not affect platelet thromboxane synthesis or platelet aggregation. 
With all the shear stress waveforms platelet thromboxane release was enhanced, while 
decreased platelet aggregation was observed. These results are in contrary to our 
expectations. One possible explanation for the mismatch between thromboxane release 
and platelet aggregation is that local transient platelet aggregation may have been 
occurred while platelets were being sheared in the cone-plate shearing device122 resulting 
in decreased platelet count, and consumption of required aggregation factors. Such a 
decrease in platelets and aggregation factors could have been possibly caused a decrease 
in post shearing aggregation at the end of 60 min shearing.  
Besides that, platelet aggregates formed were exposed to continuous shearing 
(while were being sheared) which could potentially resulted in disaggregation of platelet 
clots and prevented platelets from further agonist induced aggregation. Thus, we cannot 
draw firm conclusions regarding the effect of shear stress on platelet aggregation in this 
model system. Further studies are needed to determine whether platelet aggregation 
during the shearing period confounded the post shear aggregation measurements. If so, 
the cone-plate system may need to be optimized in future experiments. Incorporating an 
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aggregation measurement device to measure the light transmittance in the cone-plate 
shearing device would facilitate understanding of the effect of shear stress on platelets.  
Platelet thromboxane release in different shear conditions were not different, even 
the pulsatile normal shear stress with lowest shear stress-exposure duration value 
produced about the maximum level of thromboxane similar to that of elevated constant 
shear stress. It could be possible that platelets exposed to shear stress for 60 min are 
producing thromboxane up to their maximum capacity that is why we could not observe 
any difference between shear stress conditions. Previous studies have reported basal 
plasma TXB2 concentration as less than 2 pg/mL, which is subjected to transient (t1/2 = 5-
7 min) excretion to urinary metabolites in normal human circulation125;126. This in vitro 
study on the other hand shows higher concentration of plasma TXB2 which could 
possibly indicate the saturation level of thromboxane generation by platelets under the 
experimental conditions. Study with varying shear exposure duration is required to 
investigate the effect on the change in platelet thromboxane synthesis.  
Additionally, the shearing device used in this study has a limitation that there is 
some loss of sample volume due to evaporation during shearing127;128 for longer exposure 
duration (60 min). Concentration of the samples may have thus caused artifactual platelet 
TXB2 accumulation after shear exposure. Above all, the present study was not designed 
to capture the change in shear induced platelet aggregation and TXB2 concentration 
during exposure to shear stress. Study is required to investigate platelet aggregation and 
TXB2 concentration during shearing.  
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5.5 Overall Summary 
 To summarize, based on the background study and current hypothesis increased 
platelet activation and aggregation was expected from this study. Both SHS and altered 
constant shear stress have been found to have significant increase in platelet activation, 
aggregation and thromboxane generation from previous studies, which are described in 
the background section. The combined effect of SHS and altered constant shear stress 
was expected to further enhance platelet functional changes following the trend of 
individual effect. 
 The effect of dynamic shear stress on platelet activation is insignificant, whereas 
the effect is not determined on platelet aggregation for in vitro studies. Significant 
enhancement by the combined effect of SHS and altered dynamic shear stress was not 
expected to observe on platelet aggregation. Combined effect of SHS and dynamic shear 
stress on platelet thromboxane generation also was expected to increase further following 
the increased expression by dynamic shear stress and SHS. Table 5.1 shows a comparison 
between expected and observed results from this study for platelet activation and 
aggregation parameters under different experimental conditions. 
Expected trend of combined effect was reflected in the observed results that can 
be seen in the table 5.1 for platelet activation. The combined effect of shear stress and 
SHS on platelet aggregation and thromboxane generation did not match the expected 
trend.  
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Table 5.1: Summary of hypothesized and observed effect of SHS and shear stress on 
platelet activation and aggregation. SS – shear stress, Const – constant shear stress, Dyn – 
dynamic shear stress, and N.S. – not significant. 
End Point Characteristics 
Expected Observed 
SS 
SHS 
SS + SHS SS 
SHS 
SS + SHS 
Const Dyn Const Dyn Const Dyn Const Dyn 
Platelet 
Activation 
P-selectin 
expression 
↑ N.S. ↑ ↑ ? ↑ N.S. ↑ ↑ N.S. 
Platelet 
Aggregation 
Aggregation 
rate 
↑ ? ↑ ↑ ? ↓ ↓ N.S. N.S. N.S. 
Percentage of 
aggregation 
↑ ? ↑ ↑ ? ↓ ↓ N.S. NS N.S. 
Maximum 
aggregation 
percentage 
↑ ? ↑ ↑ ? ↓ ↓ N.S. N.S. N.S. 
Thromboxane 
B
2
 generation ↑ ↑ ↑ ↑ ↑ ↑ ↑ N.S. N.S. N.S. 
 
To sum up, this study investigated the interaction between SHS and altered shear 
stress and their effect on platelet functions (activation, aggregation). Alteration in normal 
platelet functions could be detrimental for the cardiovascular system. The findings from 
this study indicate that, exposure of platelets to side stream smoke and elevated constant 
shear stress under experimental conditions had increased platelet activation. However, 
platelet aggregation and thromboxane synthesis were not altered by the combination of 
SHS and shear stress. Hence, we conclude that exposure to SHS could potentially 
increases shear induced platelet activation (P-selectin expression), but has no significant 
effect on platelet aggregation.  
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5.6 Limitations  
Under normal conditions, interaction between platelets and other cells in the 
vasculature (like endothelial cell, white blood cell, leukocyte etc.) can influence platelet 
functions. Such cellular interactions were not possible to incorporate in this study. This is 
another limitation of this study. Washed platelets and platelet rich plasma were used to 
investigate the change in platelet functions, which is a further limitation of this study 
since washed platelets and platelet rich plasma are not found in vivo. Additionally, some 
protective mechanisms may work in parallel to platelet functions in physiological system, 
which are absent in the in vitro study. Finally, although by using the hemodynamic cone-
plate shearing device we tried to mimic the shear stress waveforms generated in 
physiological systems, the shearing was not completely physiological. Volume loss of the 
shearing sample is also a limitation of the cone-plate shearing device. 
Transient response of platelet functional changes was not designed to capture in 
this study. Further study is required to investigate the effect of combined exposure of 
SHS and altered shear stress on platelet functional changes like aggregation and 
thromboxane generation. Besides that, post shearing agonist induced aggregation 
measurement using aggregometer shows the relative aggregation potential after 
treatments, so it was difficult to differentiate the effects of experimental conditions from 
the results. Alternative aggregation measurement methods like measuring change in light 
transmittance through PRP in the shearing device122, or using flow cytometry before and 
after shearing could be more effective to study the combined effect on platelet 
aggregation129;130.  
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CHAPTER VI 
 
 
CONCLUSION 
 
The global aim of this study was to investigate the effect of secondhand/ 
sidestream smoke and pathological shear stress on platelet activation and aggregation.  
Pathogenesis of cardiovascular disease (CVD) alters local blood flow conditions in a 
particular vasculature. Altered shear stress distribution causes enhanced platelet 
activation and aggregation. However, the role of secondhand smoke exposure on shear 
induced platelet functions has not been established so far. The results from this study 
revealed that secondhand smoke (SHS) exposure aggravated shear induced platelet 
responses under the specified conditions, and resulted in enhanced platelet activation as 
observed by enhanced expression of platelet surface P-selectin expression. In addition, 
SHS and shear stress together could alter the platelet aggregation response. However, the 
alteration of normal platelet aggregation was not accompanied by an increase in the 
expression of the platelet surface GPIbα or GPIIb receptor. Further study is required to 
investigate the mechanism behind the changes observed. The observations from this 
study indicate that, exposure to environmental SHS can potentially cause detrimental  
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effects on the cardiovascular system by enhancing platelet activation which poses the risk 
of CVD progression, especially in patients diagnosed with CVD  
6.1 Recommendations 
 Future studies should incorporate endothelial cells with platelets to look at the 
combined effect of altered shear stress and SHS on platelets in the presence of adjacent 
cells. Transient platelet responses should be captured by varying treatment time duration 
to capture the changes of responses due to the treatment effect with time. In using cone-
plate shearing device, future study should investigate if the shearing treatment is affecting 
the post shear aggregation measurements. The cone-plate system may need to be 
customized to avoid the interference with treatment effect. Besides that more effective 
method should be chosen for aggregation measurement to quantify the aggregation rather 
than measuring the relative post treatment aggregation. The aggregation measurement 
methods could be improved by measuring change in light transmittance through PRP in 
the shearing device or using flow cytometry before and after treatment for platelet 
aggregation detection. 
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APPENDICES 
 
 
A. BASIC PROGRAMS USED FOR CONE-PLATE SHEARING DEVICE 
 
1. Program for Constant Shear Stress Experiments  
 
rem 2667 is 2.4 dynes/cm2 and 10004 is for 9 dynes/cm2  
 
joff  
sposx 0  
accx 0  
B = 1111  
velx B  
jogx  
0  
end  
$  
 
2. Programs for Dynamic Shear Stress Experiments  
 
Normal Shear Stress 
 
joff  
300  
sposx 0  
accx 0  
A = 332  
B = 308  
C = 360  
velx A  
jogx  
wait 250  
 
100  
A = A + B  
velx A
82 
 
wait 10  
if A > 11108 then goto 200  
goto 100  
200  
A = A - C  
velx A  
wait 10  
if A > 340 then goto 200  
goto 300  
end  
$  
Stenosis Shear Stress 
joff  
N = 0  
300  
sposx 0  
accx 0  
N = N+1  
A = 332  
B = 308  
C = 360  
velx A  
jogx  
wait 250  
100  
A = A + B  
velx A  
wait 10  
if A > 11108 then goto 200  
goto 100  
200  
A = A - C  
velx A  
wait 10  
if A > 340 then goto 200  
if N < 70 then goto 300  
velx 72000  
jogx  
wait 1000  
N = 0  
goto 300  
end  
$ 
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B. MATLAB PROGRAM USED FOR CALCULATING AGGREGATION 
PARAMETERS 
 
%|Output is the following (by column): 
%|1) Slope between 0-60sec, 2) Slope between 61-120sec, 3) Slope between 
%|121-180sec, 4)Slope between 181-240sec, 5) Slope between 241-300sec, 
%|6)Slope from start to level off point, 7) Time at level off, 8)Value at 
%|level off, 9) Avg value from level off to end, 10) Absolute value change 
%|from begining to level off (avg), 11) Perecent change from beginning to level 
%|off (avg) 
%|Developed by D. Rubenstein January 2008 
%|------------------------------------------------------------------ 
 
% Inputs for the program to work 
A=input('What is the name of the text file that you want to load? (use single quotes and 
full file name test.txt) '); 
B=load (A); % sets B as the geometry file, with all of the data 
C=size(B); 
 
data=zeros(C(2)-1,11); 
% Loops to calculate the regression lines 
for i=2:C(2) 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ii=1:61 %calculates slope during first minute 
        x=x+B(ii,1); 
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        x_sq=x_sq+B(ii,1).^2; 
        y=y+B(ii,i); 
        xy=xy+B(ii,1)*B(ii,i); 
    end 
    D=[61,x;x,x_sq]\[y;xy]; 
    data(i-1,1)=D(2); 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ii=62:121 %calculates slope during second minute 
        x=x+B(ii,1); 
        x_sq=x_sq+B(ii,1).^2; 
        y=y+B(ii,i); 
        xy=xy+B(ii,1)*B(ii,i); 
    end 
    D2=[60,x;x,x_sq]\[y;xy]; 
    data(i-1,2)=D2(2); 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ii=122:181 %calculates slope during third minute 
        x=x+B(ii,1); 
        x_sq=x_sq+B(ii,1).^2; 
        y=y+B(ii,i); 
        xy=xy+B(ii,1)*B(ii,i); 
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    end 
    D3=[60,x;x,x_sq]\[y;xy]; 
    data(i-1,3)=D3(2); 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ii=182:241 %calculates slope during fourth minute 
        x=x+B(ii,1); 
        x_sq=x_sq+B(ii,1).^2; 
        y=y+B(ii,i); 
        xy=xy+B(ii,1)*B(ii,i); 
    end 
    D4=[60,x;x,x_sq]\[y;xy]; 
    data(i-1,4)=D4(2); 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ii=242:301 %calculates slope during fifth minute 
        x=x+B(ii,1); 
        x_sq=x_sq+B(ii,1).^2; 
        y=y+B(ii,i); 
        xy=xy+B(ii,1)*B(ii,i); 
    end 
    D5=[60,x;x,x_sq]\[y;xy]; 
    data(i-1,5)=D5(2); 
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end 
 
% this is code to find the spot where the slope levels off 
for j=2:C(2) 
    for jj=1:C(1) 
        if jj == C(1)-29 
            data(j-1,7)=B(jj,1); 
            data(j-1,8)=B(jj,j); 
            break 
        else 
            E=0.03*B(jj,j); % a five percent error rate is assumed exceptable 
            E_min=B(jj,j)-E; % lower boundary for comparision 
            E_max=B(jj,j)+E; % upper boudnary for comparison 
            dummy=0; 
            for jjj=jj+1:jj+30 % checks for the nearest 30 if it is within that range 
                if B(jjj,j) >= E_min 
                    if B(jjj,j) <= E_max 
                    else 
                        break 
                    end 
                else 
                    break 
                end 
                dummy=dummy+1; 
            end 
            if dummy == 30 
                data(j-1,7)=B(jj,1); 
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                data(j-1,8)=B(jj,j); 
                if data(j-1,8) == 0 
                    data(j-1,7)=B(jj-30,1); 
                    data(j-1,8)=B(jj-30,j); 
                end 
                break 
            end 
        end             
    end 
end 
 
for l=2:C(2) 
    final=data(l-1,7); 
    x=0; 
    x_sq=0; 
    y=0; 
    xy=0; 
    for ll=1:final+1 %calculates slope between first and point where the slope levels off 
        x=x+B(ll,1); 
        x_sq=x_sq+B(ll,1).^2; 
        y=y+B(ll,l); 
        xy=xy+B(ll,1)*B(ll,l); 
    end 
    D6=[ll,x;x,x_sq]\[y;xy]; 
    data(l-1,6)=D6(2); 
end 
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for m=2:C(2) 
    level_sum=0; 
    count=0; 
    final=data(m-1,7); 
    for mm=final+1:C(1) 
        if B(mm,m)==0 
            break 
        else 
            level_sum=level_sum+B(mm,m); 
            count=count+1; 
        end 
    end 
    data(m-1,9)=level_sum/count; 
    data(m-1,10)=B(1,m)-data(m-1,9); 
    data(m-1,11)=(data(m-1,10)/B(1,m))*100; 
end 
 
save data.txt data -ASCII 
clear A B C D D2 D3 D4 D5 D6 E E_max E_min count data dummy final 
clear i ii j jj jjj l  level_sum ll m mm x x_sq xy y
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